The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
Metformin therapy lowers blood glucose in type 2 diabetes by targeting various pathways including hepatic gluconeogenesis. Despite widespread clinical use of metformin the molecular mechanisms by which it inhibits gluconeogenesis either acutely through allosteric and covalent mechanisms or chronical...
Main Authors: | Loranne Agius, Brian E. Ford, Shruti S. Chachra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/9/3240 |
Similar Items
-
The Protective Role of the Carbohydrate Response Element Binding Protein in the Liver: The Metabolite Perspective
by: Loranne Agius, et al.
Published: (2020-11-01) -
Phytomodulatory proteins promote inhibition of hepatic glucose production and favor glycemic control via the AMPK pathway
by: Keciany Alves de Oliveira, et al.
Published: (2019-01-01) -
Unraveling the Regulation of Hepatic Gluconeogenesis
by: Xueping Zhang, et al.
Published: (2019-01-01) -
Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway
by: Fan Bai, et al.
Published: (2019-05-01) -
Antitumor mechanisms of metformin: Signaling, metabolism, immunity and beyond
by: Ismael Samudio, et al.
Published: (2010-08-01)